Spinal Muscular Atrophy Market, by Type (Type I, Type II, Type III, and Type IV), by Treatment (Gene Therapy and Disease-modifying drugs), by Age Group (Infant and Adult), by Route of Administration (Oral and Injectables), by Distribution Channel (Hospita

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $4,500	156 Pages	Coherent Market Insights	March, 2024	CMI18685419

Best Price Guarantee
Price	from $4,500
Length	156 Pages
Publisher	Coherent Market Insights
Published Date	March, 2024
SKU	CMI18685419

Spinal Muscular Atrophy Market, by Type (Type I, Type II, Type III, and Type IV), by Treatment (Gene Therapy and Disease-modifying drugs), by Age Group (Infant and Adult), by Route of Administration (Oral and Injectables), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2024 - 2031

Spinal muscular atrophy (SMA) is a genetic disease that affects the peripheral nervous system, central nervous system, and voluntary muscle movement (skeletal muscle). SMA is muscular since it primarily affects muscles, which do not receive impulses from the nerve cells. Atrophy is the medical term for shrinking, which is what muscles do when they are not stimulated by nerve cells. SMA is a motor neuron disease that includes the loss of nerve cells termed motor neurons in the spinal cord. It mostly affects infants and children but can also develop in adults. An individual with SMA inherits two copies of a faulty (mutated) or missing survival motor neuron 1 (SMN1) gene.

Market Dynamics

The increasing product launches by the key players in the market are expected to drive the market growth over the forecast period. For instance, in August 2021, Chugai Pharmaceutical Co., Ltd., a drug manufacturer operating in Japan, announced that it had launched Evrysdi Dry Syrup 60 mg (generic name: risdiplam) for the treatment of spinal muscular atrophy (SMA).

Moreover, the increasing adoption of inorganic strategies such as partnerships and collaborations by the key players is expected to drive the market growth over the forecast period. For instance, in March 2021, the Spinal Muscular Atrophy Foundation, the leading funder of SMA research worldwide, and PTC Therapeutics, Inc., a U.S. based pharmaceutical company, entered into a new collaboration focused on developing new treatments and regenerative medicine to further advance scientific research in SMA and other neuromuscular disorders.

Key features of the study:

This report provides in-depth analysis of the global spinal muscular atrophy market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2024–2031), considering 2023 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global spinal muscular atrophy market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Biogen, CYTOKINETICS, Hoffmann-La Roche Ltd, Genentech, Inc., PTC Therapeutics, Inc., Novartis AG, Ionis Pharmaceuticals, Chugai Pharmaceutical Co., Ltd., NMD PHARMA A/S, and Astellas Pharma Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global spinal muscular atrophy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts1
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global spinal muscular atrophy market

Detailed Segmentation:

Global Spinal Muscular Atrophy Market, By Type:
Type I
Type II
Type III
Type IV
Global Spinal Muscular Atrophy Market, By Treatment:
Gene Therapy
Disease-modifying drugs
Global Spinal Muscular Atrophy Market, By Age Group:
Infant
Adult
Global Spinal Muscular Atrophy Market, By Route of Administration:
Oral
Injectables
Global Spinal Muscular Atrophy Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Spinal Muscular Atrophy Market, By Region:
North America
Latin America
Europe
Asia Pacific
Middle East & Africa
Company Profiles
Biogen
CYTOKINETICS
Hoffmann-La Roche Ltd
Genentech, Inc.
PTC Therapeutics, Inc.
Novartis AG
Ionis Pharmaceuticals
Chugai Pharmaceutical Co., Ltd.
NMD PHARMA A/S
Astellas Pharma Inc

1. Research Objectives and Assumptions: Research Objectives; Assumptions; Abbreviations
2. Market Purview: Report Description; Market Definition and Scope; Executive Summary; Market Snapshot, By Type; Market Snapshot, By Treatment; Market Snapshot, By Age; Market Snapshot, By Route of Administration; Market Snapshot, By Distribution Channel; Market Snapshot, By Region; Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis: Market Dynamics; Drivers; Restraints; Market Opportunities; Impact Analysis; Market Trends; Acquisitions and Partnerships Scenario; Technological Advancements; Regulatory Scenario; PEST Analysis; Product Launches
4. Global Spinal Muscular Atrophy Market- Impact of Coronavirus (Covid-19) Pandemic: Overall Impact; Government Initiatives; COVID-19 Impact on the market
5. Global Spinal Muscular Atrophy Market, By Type, 2019 – 2031, (US$ Million): Overview; Market Share Analysis, 2024 and 2031 (%); Y-o-Y Growth Analysis, 2020 – 2031; Segment Trends; Type I; Overview; Market Size and Forecast, and Y-o-Y Growth, 2019–2031, (US$ Million); Type II; Overview; Market Size and Forecast, and Y-o-Y Growth, 2019–2031, (US$ Million); Type III; Overview; Market Size and Forecast, and Y-o-Y Growth, 2019–2031, (US$ Million); Type IV; Overview; Market Size and Forecast, and Y-o-Y Growth, 2019–2031, (US$ Million)
6. Global Spinal Muscular Atrophy Market, By Treatment, 2019 – 2031, (US$ Million): Overview; Market Share Analysis, 2024 and 2031 (%); Y-o-Y Growth Analysis, 2020 – 2031; Segment Trends; Gene Therapy; Overview; Market Size and Forecast, and Y-o-Y Growth, 2019–2031, (US$ Million); Disease-modifying drugs; Overview; Market Size and Forecast, and Y-o-Y Growth, 2019–2031, (US$ Million)
7. Global Spinal Muscular Atrophy Market, By Age, 2019 – 2031, (US$ Million): Overview; Market Share Analysis, 2024 and 2031 (%); Y-o-Y Growth Analysis, 2020 – 2031; Segment Trends; Infant; Overview; Market Size and Forecast, and Y-o-Y Growth, 2019–2031, (US$ Million); Adult; Overview; Market Size and Forecast, and Y-o-Y Growth, 2019–2031, (US$ Million)
8. Global Spinal Muscular Atrophy Market, By Route of Administration, 2019 – 2031, (US$ Million): Overview; Market Share Analysis, 2024 and 2031 (%); Y-o-Y Growth Analysis, 2020 – 2031; Segment Trends; Oral; Overview; Market Size and Forecast, and Y-o-Y Growth, 2019–2031, (US$ Million); Injectables; Overview; Market Size and Forecast, and Y-o-Y Growth, 2019–2031, (US$ Million)
9. Global Spinal Muscular Atrophy Market, By Distribution Channel, 2019 – 2031, (US$ Million): Overview; Market Share Analysis, 2024 and 2031 (%); Y-o-Y Growth Analysis, 2020 – 2031; Segment Trends; Hospital Pharmacies; Overview; Market Size and Forecast, and Y-o-Y Growth, 2019–2031, (US$ Million); Retail Pharmacies; Overview; Market Size and Forecast, and Y-o-Y Growth, 2019–2031, (US$ Million); Online Pharmacies; Overview; Market Size and Forecast, and Y-o-Y Growth, 2019–2031, (US$ Million)
10. Global Spinal Muscular Atrophy Market, By Region, 2019 – 2031, (US$ Million): Introduction; Market Share Analysis, By Region, 2024 and 2031 (%); Y-o-Y Growth Analysis, For Regions, 2020–2031; Regional Trends; North America; Introduction; Market Size and Forecast, and Y-o-Y Growth, By Type, 2019 - 2031, (US$ Million); Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2019 - 2031, (US$ Million); Market Size and Forecast, and Y-o-Y Growth, By Age, 2019 - 2031, (US$ Million); Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (US$ Million); Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (US$ Million); Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 – 2031, (US$ Million); U.S.; Canada; Latin America; Introduction; Market Size and Forecast, and Y-o-Y Growth, By Type, 2019 - 2031, (US$ Million); Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2019 - 2031, (US$ Million); Market Size and Forecast, and Y-o-Y Growth, By Age, 2019 - 2031, (US$ Million); Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (US$ Million); Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (US$ Million); Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 – 2031, (US$ Million); Brazil; Mexico; Argentina; Rest of Latin America; Europe; Introduction; Market Size and Forecast, and Y-o-Y Growth, By Type, 2019 - 2031, (US$ Million); Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2019 - 2031, (US$ Million); Market Size and Forecast, and Y-o-Y Growth, By Age, 2019 - 2031, (US$ Million); Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (US$ Million); Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (US$ Million); Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 – 2031, (US$ Million); UK; Germany; Italy; France; Spain; Russia; Rest of Europe; Asia Pacific; Introduction; Market Size and Forecast, and Y-o-Y Growth, By Type, 2019 - 2031, (US$ Million); Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2019 - 2031, (US$ Million); Market Size and Forecast, and Y-o-Y Growth, By Age, 2019 - 2031, (US$ Million); Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (US$ Million); Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (US$ Million); Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 – 2031, (US$ Million); China; India; Japan; ASEAN; Australia; South Korea; Rest of Asia Pacific; Middle East; Introduction; Market Size and Forecast, and Y-o-Y Growth, By Type, 2019 - 2031, (US$ Million); Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2019 - 2031, (US$ Million); Market Size and Forecast, and Y-o-Y Growth, By Age, 2019 - 2031, (US$ Million); Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (US$ Million); Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (US$ Million); Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 – 2031, (US$ Million); GCC; Israel; Rest of Middle East; Africa; Introduction; Market Size and Forecast, and Y-o-Y Growth, By Type, 2019 - 2031, (US$ Million); Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2019 - 2031, (US$ Million); Market Size and Forecast, and Y-o-Y Growth, By Age, 2019 - 2031, (US$ Million); Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (US$ Million); Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (US$ Million); Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2019 – 2031, (US$ Million); North Africa; Central Africa; South Africa
11. Competitive Landscape: Biogen; Company Highlights; Product Portfolio; Key Highlights; Financial Performance; Market Strategies; CYTOKINETICS; F. Hoffmann-La Roche Ltd; Genentech, Inc.; PTC Therapeutics, Inc.; Novartis AG; Ionis Pharmaceuticals; Chugai Pharmaceutical Co., Ltd.; NMD PHARMA A/S; Astellas Pharma Inc.
12. Analyst Recommendation: Wheel of Fortune; Analyst View; Coherent Opportunity Map
13. Section: References; Research Methodology; About Us and Sales Contact